1. Home
  2. ICUI vs HAE Comparison

ICUI vs HAE Comparison

Compare ICUI & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUI
  • HAE
  • Stock Information
  • Founded
  • ICUI 1984
  • HAE 1971
  • Country
  • ICUI United States
  • HAE United States
  • Employees
  • ICUI N/A
  • HAE N/A
  • Industry
  • ICUI Medical/Dental Instruments
  • HAE Medical/Dental Instruments
  • Sector
  • ICUI Health Care
  • HAE Health Care
  • Exchange
  • ICUI Nasdaq
  • HAE Nasdaq
  • Market Cap
  • ICUI 3.0B
  • HAE 3.3B
  • IPO Year
  • ICUI 1992
  • HAE 1991
  • Fundamental
  • Price
  • ICUI $133.13
  • HAE $52.35
  • Analyst Decision
  • ICUI Buy
  • HAE Buy
  • Analyst Count
  • ICUI 6
  • HAE 10
  • Target Price
  • ICUI $186.60
  • HAE $84.20
  • AVG Volume (30 Days)
  • ICUI 314.3K
  • HAE 900.7K
  • Earning Date
  • ICUI 11-11-2025
  • HAE 11-06-2025
  • Dividend Yield
  • ICUI N/A
  • HAE N/A
  • EPS Growth
  • ICUI N/A
  • HAE 46.89
  • EPS
  • ICUI N/A
  • HAE 3.28
  • Revenue
  • ICUI $2,372,504,000.00
  • HAE $1,346,046,000.00
  • Revenue This Year
  • ICUI N/A
  • HAE N/A
  • Revenue Next Year
  • ICUI N/A
  • HAE $6.50
  • P/E Ratio
  • ICUI N/A
  • HAE $16.39
  • Revenue Growth
  • ICUI 2.96
  • HAE 0.91
  • 52 Week Low
  • ICUI $107.00
  • HAE $50.68
  • 52 Week High
  • ICUI $196.26
  • HAE $94.99
  • Technical
  • Relative Strength Index (RSI)
  • ICUI 60.24
  • HAE 30.22
  • Support Level
  • ICUI $121.61
  • HAE $53.10
  • Resistance Level
  • ICUI $136.61
  • HAE $54.52
  • Average True Range (ATR)
  • ICUI 3.76
  • HAE 1.20
  • MACD
  • ICUI 1.09
  • HAE 0.53
  • Stochastic Oscillator
  • ICUI 78.47
  • HAE 3.17

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: